$DERM

Journey Medical Corp (DERM) is experiencing a period of high volatility, with recent short-term gains but a long-term downward trend. The company's stock performance over the past year shows a significant decline, reflecting skepticism about its growth and financial management despite some analyst "buy" ratings from smaller firms. Investors are advised to be cautious, as the stock sits at an inflection point, requiring clear evidence of sustained revenue growth and operational improvements to justify a higher valuation.